{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-286070","form_type":"8-K","ticker":"SLDB","cik":"0001707502","company_name":"Solid Biosciences Inc.","filed_at":"2021-09-29T23:59:59+00:00","discovered_at":"2026-05-14T18:04:19.300938+00:00","generated_at":"2026-06-29T00:44:27.107641+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Solid Biosciences reports improved pulmonary function in DMD gene therapy trial, controls decline","bullets":["PEF % predicted improved in all 4 evaluable dosed patients (+2.5% to +38.5%); 2 evaluable controls declined (-1.1%, -18.2%) at one year.","FEV1 % predicted improved in all 5 evaluable dosed patients (+2.8% to +15.5%); all 3 evaluable controls declined (-8.7% to -17.0%).","Data from first 6 patients in Phase I/II IGNITE DMD trial of SGT-001; presented at Child Neurology Society 50th Annual Meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-286070","json":"https://secwatch.observer/filing/0001193125-21-286070.json","markdown":"https://secwatch.observer/filing/0001193125-21-286070.md","text":"https://secwatch.observer/filing/0001193125-21-286070.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1707502/000119312521286070/0001193125-21-286070-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1707502/000119312521286070/d230511d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T00:44:27.107641+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}